Share This Page
Drug Price Trends for SM STAY AWAKE
✉ Email this page to a colleague

Average Pharmacy Cost for SM STAY AWAKE
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.07996 | EACH | 2025-01-22 |
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.07974 | EACH | 2024-12-18 |
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.07950 | EACH | 2024-11-20 |
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.08010 | EACH | 2024-10-23 |
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.08100 | EACH | 2024-09-18 |
SM STAY AWAKE 200 MG TABLET | 70677-0021-01 | 0.08182 | EACH | 2024-08-21 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Insomnia Treatments: Focus on Dual Orexin Receptor Antagonists (DORAs)
Introduction to Insomnia Market
The insomnia market, particularly within the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), is poised for significant growth driven by advancements in treatment options. Here, we delve into the market analysis and price projections, with a special focus on dual orexin receptor antagonists (DORAs), a class of drugs that has revolutionized the treatment of insomnia.
Current Market Landscape
The US dominates the insomnia market, accounting for 81.3% of the 7MM sales in 2022, and this dominance is expected to increase to 81.9% by 2032. This is attributed to the larger population of individuals with insomnia and higher drug prices in the US[1][3].
Role of Dual Orexin Receptor Antagonists (DORAs)
DORAs have emerged as a key driver in the insomnia market. These drugs, including Merck’s Belsomra (suvorexant), Eisai’s Dayvigo (lemborexant), and Idorsia’s Quviviq (daridorexant), offer a new mechanism of action by selectively inhibiting arousal and promoting sleep without affecting GABA neurotransmission. This makes them particularly effective for patients who are treatment refractory or have responded partially to older pharmacological treatments[1][3].
Market Growth Projections
The insomnia market is expected to grow at a compound annual growth rate (CAGR) of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032. This growth will be primarily driven by the increasing patient share of DORAs, which are projected to grow at a CAGR of 8.6% between 2022 and 2032[1][3].
Key Players and Pipeline Therapies
Several key players are driving the market forward with their pipeline therapies:
- Merck’s Belsomra (suvorexant): Already a market leader, Belsomra is expected to face competition from generic versions once it loses market exclusivity in the US in 2029 and in Japan in 2031[1][3].
- Eisai’s Dayvigo (lemborexant): Similar to Belsomra, Dayvigo will lose market exclusivity in the US in 2031, allowing cheaper generic versions to enter the market[1][3].
- Idorsia’s Quviviq (daridorexant): Quviviq has been gaining patient share and is expected to continue its growth trajectory[1][3].
- Hetlioz: Forecast to generate $235.8 million in sales by 2032, primarily due to its high annual cost of therapy[3].
- Sunobinop: Expected to see good initial uptake as the first product targeting insomnia associated with substance use disorder, with projected sales of $79.2 million by 2032[3].
Challenges and Opportunities
Market Exclusivity and Generic Competition
The loss of patent exclusivity for Belsomra and Dayvigo will allow cheaper generic versions of DORAs to enter the market, leading to sales erosion for the branded products. However, the launches of pipeline therapies and the increased uptake of DORAs will continue to fuel market growth[1][3].
Drug Pricing
Higher drug prices in the US contribute significantly to the market size. However, the unique structure of the prescription drug market in the US, involving Pharmaceutical Benefit Managers (PBMs), can lead to a lack of transparency and perverse incentives that drive up drug list prices[4].
Regional Market Dynamics
US Market
The US remains the largest market for insomnia treatments, driven by a larger population of individuals with insomnia and higher drug prices. New therapies such as Hetlioz, SM-1, and sunobinop are forecast to launch exclusively in the US during the forecast period[1][3].
European Market
While the European market is smaller, it still presents significant opportunities. The launch of new therapies and the increasing adoption of DORAs will drive growth in this region as well[1].
Future Trends and Projections
Increased Adoption of DORAs
The patient share of DORAs is expected to continue growing, driven by their efficacy and the unmet need for effective insomnia treatments. This trend will be a key driver of market growth across the 7MM[1][3].
Pipeline Therapies
The introduction of new pipeline therapies, such as sunobinop and Hetlioz, will provide additional treatment options and drive market growth. Sunobinop, in particular, is expected to address insomnia associated with substance use disorder, a previously underserved segment[3].
Generic Competition
The entry of generic versions of DORAs will increase competition and potentially reduce prices, making treatments more accessible but also posing a challenge to branded products[1][3].
Key Takeaways
- The insomnia market is expected to grow at a CAGR of 2.6% from 2022 to 2032, driven by the increasing adoption of DORAs.
- The US will continue to dominate the market due to its larger population and higher drug prices.
- Pipeline therapies such as Hetlioz and sunobinop will contribute to market growth.
- The loss of patent exclusivity for branded DORAs will lead to the entry of generic versions, affecting sales of branded products.
- Higher drug prices and market exclusivity remain significant factors in the US market.
FAQs
What is the projected growth rate of the insomnia market from 2022 to 2032?
The insomnia market is expected to grow at a compound annual growth rate (CAGR) of 2.6% from $3.2 billion in 2022 to $4.1 billion in 2032[1][3].
Which region dominates the insomnia market?
The US represents the largest market for insomnia, accounting for 81.3% of the 7MM sales in 2022, increasing to 81.9% by 2032[1][3].
What are the key drivers of the insomnia market growth?
The key drivers include the increasing patient share of dual orexin receptor antagonists (DORAs) and the introduction of new pipeline therapies such as Hetlioz and sunobinop[1][3].
How will the loss of patent exclusivity affect the market?
The loss of patent exclusivity for branded DORAs will allow cheaper generic versions to enter the market, leading to sales erosion for the branded products but making treatments more accessible[1][3].
What new therapies are expected to launch in the US market?
New therapies such as Hetlioz, SM-1, and sunobinop are forecast to launch exclusively in the US during the forecast period[1][3].
Sources
- European Pharmaceutical Review: "Market outlook to 2032: future trends across the seven major markets"[1].
- Clinical Trials Arena: "Dual orexin receptor antagonists to drive insomnia market across 7MM"[3].
- Stanford Medicine: "Policy Options to Reduce Prescription Drug Costs"[4].
More… ↓